.svg)
When the BRACE Trial launched in March 2020, the team needed to recruit thousands of healthcare workers across five countries while the world was locking down. Six weeks later, the platform was live. Over 6,000 participants joined, and adherence held above 90%. That’s what good clinical trial recruitment looks like.
Most clinical trial recruitment strategies miss the mark because they treat recruitment like a marketing problem. It isn’t. Recruitment is a research design problem, a patient experience problem, and a retention problem rolled into one. Get those three right and the maths changes.
This guide walks through nine clinical trial recruitment strategies that work in the real world, the common reasons trials struggle to enrol, and a simple recruitment plan you can adapt for your own study. The examples come from studies we’ve supported through our clinical trial solutions, including the BRACE trial, GenV, and INHERIT, with notes on what each pattern looks like in practice.
Why clinical trial recruitment fails
About 80% of clinical trials miss their original enrolment timelines. Roughly one in ten investigator sites enrol no participants at all, and another third under enrol. Recruitment problems caused around 30% of phase 3 terminations in a 2024 review by Hung and colleagues. Industry analyses put the cost of a single day of trial delay between $600,000 and $8 million depending on phase and indication.
The reasons cluster into three groups: a protocol that doesn’t match the patient population, slow site activation, and a poor patient experience once people are interested. Each problem feeds the next. A restrictive protocol forces wider outreach. Wider outreach burns budget. Burnt budget pushes teams to compromise on the patient experience. Drop off rises and the cycle continues.
The fix isn’t more advertising spend. It’s better strategy at every step from protocol design through to first patient visit. The clinical trial recruitment strategies below are organised that way: fix the design first, run smarter outreach, lower the burden, and plan retention from day one.
What are the most effective clinical trial recruitment strategies?
The most effective clinical trial recruitment strategies combine patient population research, healthcare provider referrals, targeted digital advertising, multilingual outreach, simplified eConsent, decentralised study elements, and a retention plan that starts on day one. The strongest programmes treat recruitment and retention as one continuous patient experience, supported by digital tools that lower participation burden.
9 clinical trial recruitment strategies that work
1. Start with the patient population, not the protocol
The biggest cause of slow enrolment is a mismatch between the protocol and the people you need to reach. Eligibility criteria written for a “perfect” patient often exclude the very people who’d benefit most.
Before you finalise the protocol, build patient personas using EHR queries, claims data, registry estimates, and conversations with clinicians who treat the condition. A useful test: take your draft inclusion and exclusion criteria, run them against an EHR cohort, and count how many real patients qualify. If that number isn’t at least five times your enrolment target, the protocol needs work, not the recruitment plan.
For population scale studies, this approach pays off enormously. The team behind GenV designed an inclusive newborn family study around the realities of new parents, which is one reason over 100,000 families now contribute data to the project.
2. Engage healthcare providers as trusted gateways
Patients trust their GP or specialist more than any ad. A well planned referrer programme gives clinicians simple ways to flag eligible patients and track their journey into the trial.
That means a one page referral form, an eligibility checker that takes under two minutes, and feedback to the referring clinician once the patient enrols. In Australia, this often means working directly with GP networks and integrated health services. For multisite trials, site level champions matter just as much.
Across the studies we’ve supported, sites with an engaged principal investigator and a clear referrer playbook consistently enrol faster than sites without one. The strongest clinical trial recruitment strategies treat referrer engagement as an ongoing relationship, not a one off email. If a site hasn’t enrolled a patient in 30 days, ask whether the referrer pathway is working before spending more on outreach.
3. Make digital advertising work without burning budget
Digital advertising is where most recruitment budgets disappear. Untargeted social and search campaigns produce expensive clicks and few qualified participants. The teams that get value from clinical trial advertising follow three rules.
Target by condition and intent. Build a dedicated landing page for each study arm. Feed performance data back into the campaign weekly. Useful tactics include condition specific keyword campaigns, paid social with interest plus behaviour targeting, retargeting visitors who started pre screening but didn’t finish, and partnerships with patient communities and health publishers.
Track cost per qualified participant, not cost per click. A good landing page reads at a Year 8 reading level, answers the three questions every potential participant asks (Am I eligible? What’s involved? What does it cost me?), and ends with a quick pre screening form. Anything longer loses people.
4. Recruit in the languages your participants actually speak
If your protocol covers a multicultural population and you only run English materials, you’re cutting your eligible pool in half. Multilingual recruitment isn’t a nice to have. It’s the difference between a representative sample and a biased one.
The INHERIT COVID-19 study worked because every step from outreach to consent to ePRO was available in multiple languages. We worked with the team to deploy multilingual screening, consent, and study materials inside the same participant app, so people could move between languages whenever it suited them.
For Australian trials, that often means English plus Mandarin, Cantonese, Vietnamese, Arabic, and Greek as a minimum, depending on the study population. WeGuide’s multilingual study support handles translation versioning so your IRB or HREC always sees the approved version.
5. Simplify screening and eligibility
Most trials lose more candidates between “I’m interested” and “first study visit” than at any other step in the funnel. Long PDF forms, repeated questions, and ambiguous eligibility logic drive the drop off.
Move screening online with conditional logic so participants only see the questions that apply to them. Three tactical wins:
- Use a digital screening flow that pre populates known information from the referrer.
- Show a progress bar so participants know how close they are to finishing.
- Send the result, eligible, ineligible, or referred for further review, within minutes rather than days.
WeGuide’s digital screening module and Form Builder handle this end to end, with conditional logic and instant routing into eConsent for eligible participants. The shorter the gap between interest and consent, the lower your screen fail rate.
6. Use eConsent to remove the biggest enrolment friction
The consent process is the single biggest place trials lose participants. Long printed forms, jargon dense language, and an in person signature requirement add weeks to enrolment without improving comprehension.
Modern electronic informed consent replaces the PDF with an interactive flow: plain language summaries, short videos for complex concepts, comprehension checks, and an audit trail that satisfies 21 CFR Part 11 and ICH GCP requirements. Participants can read at their own pace and ask questions before signing.
Our eConsent best practices guide covers implementation in detail. The short version: shorter sentences, visual structure, and language matched to a Year 8 reading level move both comprehension and completion rates up at the same time. TGA, FDA, and EMA all accept properly designed eConsent. Bring your ethics committee in early and the timeline shrinks.
7. Lower participation burden with decentralised elements
Every clinic visit you remove from a protocol is a barrier removed. Decentralised clinical trial design uses at home visits, ePRO diaries, telehealth check ins, and wearables to keep participants in the study without forcing them to take a half day off work.
The BRACE Trial is the clearest example we’ve worked on. The team needed to enrol thousands of healthcare workers during a pandemic, and they couldn’t rely on site visits. Using decentralised trial technology, they ran the trial across five countries and 6,000 participants with adherence above 90%.
Decentralised design also widens the eligible pool. Patients who live far from the nearest site, or who have caring responsibilities at home, can now take part. That’s both a recruitment win and a diversity win.
The shift looks like this in practice:
8. Build community trust, especially in underrepresented populations
Black, Hispanic, and CALD participants remain under represented in clinical research. A 2025 scoping review by Helm and colleagues mapped the strategies that close that gap: long term partnerships with community organisations, paid patient navigators, culturally appropriate materials, and community based recruitment events that don’t require a hospital visit.
These partnerships take time, often a year or more, but they pay off across multiple trials, not just one. They also surface protocol issues that internal teams miss, like assumptions about transport, working hours, or family responsibilities.
Trust is also what makes the difference for rare disease and paediatric studies. The strongest patient registries we’ve worked on grew because patients felt heard in how the registry was designed, not because they were targeted by an ad campaign. The FDA’s diversity guidance is a useful reference when planning your approach.
9. Plan for retention from the recruitment stage
Recruitment without retention is wasted spend. If 30% of participants drop out before the primary endpoint, you’ve recruited 30% more participants than you needed at full cost.
Patient retention starts during recruitment, not after the first visit. Three things matter most: a clear patient onboarding sequence, regular contact through push notifications and patient education, and a feedback loop that lets participants see how their data is being used. Decisions made during recruitment shape treatment adherence later. The BRACE Trial held adherence above 90% for the same reason it recruited fast. Participants felt informed and supported throughout.
For long studies, WeGuide’s patient engagement platform keeps participants connected with educational content and personalised reminders that reduce drop off without overwhelming inboxes.
Common clinical trial recruitment challenges and how to fix them
Even the strongest clinical trial recruitment strategies hit the same five clinical trial recruitment challenges. Here’s how to spot them early and fix them quickly.
Slow site activation. Sites that take six months or more to activate are a red flag. Build site readiness checklists into the contract phase, not after.
Eligibility criteria that are too restrictive. Run a feasibility check against EHR data before locking the protocol. If the eligible pool is under five times your enrolment target, expand criteria where it’s safe to do so.
Drop off between consent and first visit. This is almost always a logistics issue, not a motivation issue. Reduce the gap to under two weeks, send a clear pre visit checklist, and offer at home visits where the protocol allows.
Diversity gaps. Audit each site monthly against your target diversity profile. If a site is enrolling but not reaching diverse participants, swap or add channels rather than waiting until enrolment closes.
Sponsor, CRO, and site misalignment. Recruitment problems are often communication problems. A weekly recruitment standup with site PIs, sponsors, and the digital team surfaces issues two to three weeks earlier than a monthly steering committee.
How to build a clinical trial recruitment plan
A clinical trial recruitment plan doesn’t need to be 50 pages. The teams we work with use a six step framework that fits on two pages and gets revised every fortnight.
- Define the population. Who are we trying to reach, and where do they spend time?
- Set the targets. Total enrolment, monthly enrolment per site, diversity targets, drop off ceilings.
- Choose the channels. HCP referrals, digital advertising, community partners, patient registries, in clinic outreach. Mix two to four channels, not eight.
- Set up the tech stack. Pre screening, eConsent, patient onboarding, ePRO, and engagement tools that talk to each other so data isn’t re entered at every step.
- Launch and measure. Track clinical trial enrolment metrics that matter: cost per qualified participant, time to first patient, screen failure rate, and 30 day retention. Share the dashboard weekly.
- Iterate. Move budget toward what’s working in week 4, not month 4.
This plan is also the bridge between recruitment and enrolment. Recruitment vs enrolment in clinical trials isn’t just terminology. Recruitment is everything before consent. Enrolment is everything after. Both need to be designed together, and the strongest clinical trial recruitment strategies treat them as one continuous patient journey.
How WeGuide partners with research teams on recruitment and retention
We’ve been part of a lot of recruitment plans, and the strongest clinical trial recruitment strategies share four habits. The studies that hit their numbers design for the patient first, remove friction at consent, lower visit burden, and plan patient retention into recruitment from day one.
That’s exactly what BRACE, GenV, and INHERIT have in common. We collaborated closely with each team to bring digital screening, multilingual eConsent, ePRO, and patient engagement into a single experience. The outcomes speak for themselves. BRACE enrolled 6,000 participants across five countries with adherence above 90%. GenV is engaging more than 100,000 families in a long running newborn study. INHERIT reached CALD communities at scale during the COVID-19 pandemic.
If you’re planning a study where recruitment and retention need to work together, we’d be happy to talk through how WeGuide might fit. Book a demo and we’ll walk through it with examples from real studies, not slideware.
Conclusion
Strong clinical trial recruitment strategies aren’t a list of ad channels. They’re a set of decisions that start with protocol design and run through to the final follow up.
Match the eligibility criteria to a real population. Engage clinicians as trusted gateways. Run digital advertising that’s accountable to cost per qualified participant, not cost per click. Make the consent process easy to read and easy to finish. Lower visit burden with decentralised elements. Build trust in the communities you’re under representing. And plan retention from the moment someone says they’re interested.
The trials that hit their enrolment targets aren’t the ones with the biggest marketing budgets. They’re the ones that treat recruitment and retention as the same problem, supported by digital tools that respect participant time.
If you’re planning your next study and want to talk through what a participant first clinical trial recruitment strategy could look like, explore our case studies for examples from BRACE, GenV, and other studies we’ve supported.
